BioCentury
ARTICLE | Clinical News

AVI-7288: Phase I started

May 13, 2013 7:00 AM UTC

Sarepta began a double-blind, placebo-controlled, U.S. Phase I trial to evaluate multiple ascending-doses of 1, 3, 6 and 9 mg/kg IV AVI-7288 once daily for 14 days in 32 healthy volunteers. Sarepta is...